with and without other autoantibodies present using 451 SSc patients with complete dataset. Autoantibodies to several scleroderma-related autoantibodies were detected using commercial or research use only kits (Inova Diagnostics, San Diego, USA). P-values below 0.05 were considered significant. Results: The sensitivity and specificity of anti-BICD2 antibodies were determined as 22.1% and 99.0%, respectively. Receiver operating characteristic (ROC) analysis showed an area under the curve of 0.79 (95% CI 0.75-0.84). The likelihood (LR) and odds ratios (OR) were 17.7 (LR+), 0.8 (LR-) and 20.4 (OR). The prevalence of these autoantibodies was equally distributed between limited and diffuse form of SSc (22.8% and 24.0%). When SSc patients without the classification criteria markers anti-Scl-70, anti-Centromere and anti-RNA Pol III (n=184) were compared with controls, similar performance was obtained as seen in the entire cohort. Results are summarized in table 1 below.
Background: Treatment with tocilizumab (TCZ) in early systemic sclerosis (SSc; FaSScinate trial) resulted in consistent, but not statistically significant, improvements in skin sclerosis (mRSS) at wks 24 and 48 1 . The CRISS index has been proposed as a composite index for trials in SSc 2 . CRISS is a 2-step process that assigns a probability of improvement for each subject ranging from 0.0 [no improvement] to 1.0 [marked improvement].
Step 1 assesses clinically meaningful decline in cardio-pulmonary-renal involvement and assigns a probability of 0.0. For remaining subjects, 5 variables are used to calculate probability of improvement. These are: FVC%, mRSS, patient (PT GA) and physician globals (MD GA), and HAQ-DI. Objectives: To assess the performance of CRISS index in the FaSScinate trial. Methods: In FaSScinate, pts ≥18 y with active SSc were randomized 1:1 to TCZ or placebo (PLA) for 48 wks.
Step 1 CRISS was captured using review of serious adverse event data. Non-parametric Wilcoxon test was used to assess significant differences between the CRISS scores in both arms. Analyses were carried out for subject who had complete data at baseline and 24 weeks and at baseline and 48 weeks. Results: 87 pts (43 TCZ, 44 PBO) were enrolled. Baseline characteristics were similar between arms. 4 subjects in the PBO group and none in TCZ met the pre-defined definition of worsening in Step 1 and were given a score of 0.0. For remaining subjects, we calculated probability score for each subject. Using CRISS as a continuous measure, the median score was statistically significant and favored TCZ compared to PBO at wks 24 and 48 (p=0.04 and 0.01; Table) . 
